FDA Brief

Warning letters Drugs

FDA warning letter to

NuGeneration Technologies LLC

High riskIssued Mar 13, 2023Posted Mar 28, 2023Division of Pharmaceutical Quality Operations IV

FDA inspected NuGeneration Technologies' Emeryville, California drug plant and found CGMP failures in hand sanitizer release testing, ingredient and water testing, stability and process validation.

What happened

FDA inspected NuGeneration Technologies' drug manufacturing facility at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022. Investigators found the company released its NuRinse Hand Sanitizer without full release testing, did not test incoming ethanol and deionized water, lacked stability data for expiration dates, and had not validated its manufacturing process. FDA reviewed the company's October 12, 2022 response to the Form FDA 483 (the list of observations given at the end of an inspection) and called it inadequate.

What FDA found

  1. The company released hand sanitizer batches without testing them for identity and strength of the active ingredient or for impurities and microbes.

    21 CFR 211.165(a)
  2. The company relied on certificates of analysis from unqualified ethanol suppliers and did not test each incoming lot of ethanol itself for identity.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company did not test incoming ethanol for methanol, which has caused fatal poisonings worldwide.

    21 CFR 211.84(d)(2)
  4. The company could not show its deionized water system consistently makes water meeting the USP Purified Water standard, and it did not properly test for total organic carbon, microbes, or record conductivity.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  5. The company had no stability data to support the expiration dates of hand sanitizer already in distribution.

    21 CFR 211.166(a)
  6. The company had not validated the manufacturing process for its hand sanitizer.

    21 CFR 211.100(a)

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days describing what it has done and how it will prevent recurrence; if more time is needed, it must explain the delay and give a schedule. FDA also strongly recommends hiring a qualified CGMP consultant.

Who should pay attention

  • distributors and retailers selling NuRinse hand sanitizer
  • contract manufacturers of alcohol-based hand sanitizers
  • companies that rely on supplier certificates of analysis instead of testing incoming ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk